101225-88-1 Usage
General Description
N-(3-[1,2,4]triazol-1-yl-propyl)-phthalimide is a chemical compound that belongs to the class of phthalimide derivatives. It contains a phthalimide group and a 1,2,4-triazole ring connected through a propyl spacer. N-(3-[1,2,4]triazol-1-yl-propyl)-phthalimide has potential bioactive properties and can be used as a building block in medicinal chemistry for the synthesis of various pharmaceutical compounds. It has been studied for its anti-inflammatory and analgesic properties, and it shows potential as a drug candidate for the treatment of various diseases and conditions. Additionally, its chemical structure allows for modification and optimization for specific biological activities, making it a versatile and valuable compound in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 101225-88-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,2,2 and 5 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 101225-88:
(8*1)+(7*0)+(6*1)+(5*2)+(4*2)+(3*5)+(2*8)+(1*8)=71
71 % 10 = 1
So 101225-88-1 is a valid CAS Registry Number.
101225-88-1Relevant articles and documents
Evaluation of synthetic substituted 1,2-dioxanes as novel agents against human leishmaniasis
Ortalli,Varani,Rosso,Quintavalla,Lombardo,Trombini
, p. 126 - 140 (2019)
The treatment of human leishmaniasis is currently based on few compounds that are highly toxic, expensive and have a high rate of treatment failure. A number of recent studies on new drugs focuses on natural or semi-synthetic compounds. Among them, the endoperoxide artemisinin, extracted from Artemisia annua, and some of its derivatives have shown leishmanicidal activity. In the present work, a series of structurally simple, fully synthetic 1,2-dioxanes were evaluated for in vitro antileishmanial activity against promastigotes of Leishmania donovani; the cytotoxicity for mammalian cells was also assessed. The six most promising compounds in terms of activity and selectivity were further investigated for their antileishmanial activity on the promastigote forms of L. tropica, L. major and L. infantum and against L. donovani amastigotes. The good performance in terms of potency and selectivity makes these six hits promising candidates for a preliminary lead optimization as antileishmanial agents.
